CMAS dampens anti-tumor immunity and associates with response to neoadjuvant immunotherapy in melanoma
Magalí B. Coccimiglio, Sofia Ibáñez‐Molero, Babet O. Springer, Laura J. W. Kruijssen, Georgia Clayton, Reece Davison, Tao Zhang, S C M A Wijnen, Ernesto Rodríguez, Katarzyna Olesek, S. Veenstra, Thomas van den Brekel, Eleonora Nardini, Joelle van Elk, Eelco D. Keuning, , Yvette van Kooyk
The paper shows CMAS in melanoma cells correlates with poor survival and reduced response to immunotherapy by altering tumor-immune interactions.
bioRxiv · Apr 29, 2026 · PreprintCancer Biology